Less than two years after RSV vaccines and preventive treatments became available, infant hospitalizations are already plummeting. This is prevention working exactly as intended. https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/rsv-prevention-products-tied-lower-infant-hospitalization-rates #NIAM2025 Infant hospitalization rates for respiratory syncytial virus (RSV) were 28% to 43% lower in 2024-25, the first US respiratory-virus season with broad availability of a maternal RSV vaccine (Abrysvo) and the preventive monoclonal antibody nirsevimab (Beyfortus) for infants,...